Literature DB >> 2942517

Skin reactions induced by trimetrexate, an analog of methotrexate.

R B Weiss, W D James, W B Major, M B Porter, C J Allegra, G A Curt.   

Abstract

We have observed three forms of skin toxicity induced by the new antifol trimetrexate in a Phase I trial. They are: radiation recall, cellulitis at the infusion site, and generalized skin eruptions with erythroderma. A total of 25 episodes of some form of skin reaction occurred in 31 patients. The generalized eruption began about four days after drug administration and cleared within a week. The mechanism of skin toxicity of trimetrexate and other antifols is unknown.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2942517     DOI: 10.1007/bf00194596

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  11 in total

1.  Trimetrexate: a new antifol entering clinical trials.

Authors:  P J O'Dwyer; D D Shoemaker; J Plowman; J Cradock; A Grillo-Lopez; B Leyland-Jones
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

2.  High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma.

Authors:  G Rosen; S Suwansirikul; C Kwon; C Tan; S J Wu; E J Beattie; M L Murphy
Journal:  Cancer       Date:  1974-04       Impact factor: 6.860

3.  Erythema and desquamation after high-dose methotrexate.

Authors:  L A Doyle; C Berg; G Bottino; B Chabner
Journal:  Ann Intern Med       Date:  1983-05       Impact factor: 25.391

4.  Local toxicity from iv administration of Baker's antifol.

Authors:  S H Krasnow; R H Patterson; B Fischmann; M A Eisenberger; A Johnston-Early; M L Citron; M H Cohen
Journal:  Cancer Treat Rep       Date:  1985-06

5.  Baker's antifol in children with therapy-resistant solid tumors: a Southwest Oncology Group Study.

Authors:  R Nitschke; S K Morgan; V J Land
Journal:  Cancer Treat Rep       Date:  1981 Jul-Aug

6.  Evaluation of weekly escalating doses of dichloromethotrexate in patients with hepatocellular carcinoma and other solid tumors.

Authors:  W J Tester; R C Donehower; J L Eddy; C E Myers; D C Ihde
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 7.  Hypersensitivity reactions to cancer chemotherapeutic agents.

Authors:  R B Weiss; S Bruno
Journal:  Ann Intern Med       Date:  1981-01       Impact factor: 25.391

8.  Folate antagonists. 20. Synthesis and antitumor and antimalarial properties of trimetrexate and related 6-[(phenylamino)methyl]-2,4-quinazolinediamines.

Authors:  E F Elslager; J L Johnson; L M Werbel
Journal:  J Med Chem       Date:  1983-12       Impact factor: 7.446

9.  Methotrexate-induced necrolysis.

Authors:  K M Reed; A J Sober
Journal:  J Am Acad Dermatol       Date:  1983-05       Impact factor: 11.527

10.  Phase 2 study with Baker's Antifol in solid tumors.

Authors:  V Rodriguez; S P Richman; R S Benjamin; M A Burgess; W K Murphy; M Valdivieso; R L Banner; J U Gutterman; G P Bodey; E J Freireich
Journal:  Cancer Res       Date:  1977-04       Impact factor: 12.701

View more
  10 in total

Review 1.  Hypersensitivity reactions from antineoplastic agents.

Authors:  R B Weiss; J R Baker
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

2.  A phase I and pharmacokinetic study of trimetrexate using a 24-hour continuous-injection schedule.

Authors:  C J Allegra; J Jenkins; R B Weiss; F Balis; J C Drake; J Brooks; R Thomas; G A Curt
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

3.  Hypersensitivity reactions to trimetrexate.

Authors:  J L Grem; S A King; M E Costanza; T D Brown
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

4.  Locoregional interaction of ixabepilone (ixempra) after breast cancer radiation.

Authors:  Vinita Takiar; Eric A Strom; Donald P Baumann; Funda Meric-Bernstam; Ricardo H Alvarez; Ana M Gonzalez-Angulo
Journal:  Oncologist       Date:  2013-02-12

5.  A phase I study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections.

Authors:  J Jolivet; L Landry; M F Pinard; J J McCormack; W P Tong; E Eisenhauer
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Phase I clinical trial and human pharmacokinetics of 2,4-diamino-5-adamantyl-6-methyl pyrimidine ethane sulfonate (DAMP-ES): a lipid-soluble antifolate.

Authors:  P J Creaven; S F Zakrzewski; W R Greco; S Madajewicz; A Mittelman; J E Pontes; C Karakousis; H Takita; A Proefrock
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil.

Authors:  G R Hudes; F LaCreta; R J DeLap; A J Grillo-Lopez; R Catalano; R L Comis
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

8.  Phase II trial of trimetrexate in patients with advanced soft-tissue sarcoma.

Authors:  J D Licht; R Gonin; K H Antman
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 9.  Radiation recall with anticancer agents.

Authors:  Howard A Burris; Jane Hurtig
Journal:  Oncologist       Date:  2010-11-02

10.  Radiation recall dermatitis: case report and review of the literature.

Authors:  A E Hird; J Wilson; S Symons; E Sinclair; M Davis; E Chow
Journal:  Curr Oncol       Date:  2008-01       Impact factor: 3.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.